PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), today announced completion of two randomized and controlled clinical trials of Microcyn® Technology in China conducted by Oculus’ partner, China Bao Tai. The trial data has been submitted to the Chinese State Food and Drug Administration (SFDA) as the final step in securing agency approval to market Microcyn-based products in China. Results will be made available upon publication of the studies in the appropriate medical journals
